PHARMACEUTICAL wholesaler, Sigma Healthcare, will not generate sufficient franking credits to pay a fully franked dividend for the 2020 Financial Year.
In a statement to the Australian Securities Exchange (ASX), Sigma said that while it was on target to deliver an underlying earnings before interest, tax, depreciation and amortisation guidance of approximately $46-47 million for the current year, one-off costs associated with the transformation of the business had impacted its ability to deliver a fully franked dividend.
Sigma CEO, Mark Hooper, said the business expected to see accelerated underlying earnings in 2021, stemming from the group's core business.
Guidance for FY21 will be provided next month.
The above article was sent to subscribers in Pharmacy Daily's issue from 10 Feb 20
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Feb 20
